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Amiodaronc Effect on Defibrillation Energy Requirement. Introdtiction: The effect of
oral uiniodurone therapy on delibrillaliun energj requirements in patients with an implantable
defibrillator has not heen estahlished.
Methods and Results: Twenty-one consecutive patients with implantahle hiphasic waveform
defibrillators underwent a step-down determination of the defihrlllatlon energy re(|uirenient 211 ±
12 days before and 73 ± 22 days after initiation of amiodarone therapy (mean total dose 26.7 ±
11.1 jil. Serum amiodaronc and desethylamiodarone concentrations were measured at the time of
dehbrillation energy requirement determination. The mean defibrillation energy requirement hefore
amiodarone therapy was 9.9 ± 4.6 J. After initiation of amiodarone therapy, the mean defihrillation
energy requirement increa.sed to 13.7 ± 5.6 J (P = 0.0041. .\ linear relationship hetween the
amiodarone (P = 0.02. r = 0.6). desethylamiodarone (P = 0.02, r = 0.6). and combined amiodarone-
desethylamiodarone concentrations (P = O.OI. r = 0.6) and the dehhrillation energy requirement
was noted. Stepwise regression analysis demonstrated that the comhined amiodarone-desethylami-
odarone concentration was the only independent predictor of increa.sc in the defihrillation energy
requirement.
Conclusion: Chronic oral amiodarone therapy increases the defibrillation energy requirement hy
approximately 62% in patients with an implantahle defibrillat(tr. The comhined aniiodarone-
desethylamiodarone concentration is directly related to the increase in the defihrillation energy
requirement. (J Cardiovasc Electrophysiol. Vol. 11. pp. 736-740, July 2000)
implantable defihrillator, ventricular fibrillation, defibrillation threshold
Introduction
Amitxlarone i.s commonly prescribed for patients with
an implantable defibrillator who receive frequent shocks
for alrial or venlricular arrhythmias.'-' The effect of
amiodarone on the defibrillation energy requirement is
unclear. Indirect evidence suggests that amiodarone ele-
vates monophasic detibriiiation energy requirements.^**
However, a prospective comparison of detibriiiation en-
ergy requirements before and after chronic amicKlarone
administration in piitients with an irnpkiniable detibrilla-
tor has not been reported. The purpo.se ot this study was
to determine prospectively the effect of chronic amioda-
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rone therapy on the detibriiiation energy requirement in
patients with an implantable detibriliator.
Methods
Patient Population
The study population consisted of 21 patients (19 men
and 2 women, mean age 64 ± 15 years) with an implant-
able delibrillalur baving biphiisic wavct'itrms who were
treated with amiodarone (Tiible I). Mean left ventricular
ejection fraction was 0.31 ± 0.13. Coronary artery dis-
ease was present in 13 patients, nonischemic cardiomy-
opathy was present in 7 patients, and I patient bad no
structural heart disease. The indication for implantable
detibrillator placement was aborted sudden cardiac death
in 8 patients, sustained ventricular tachycardia in 6. syn-
cope in 4, and nonsustained ventricular tachycardia in 3.
The indication for amiodarone therapy was atrial tibril-
iation in 13 patients and frequent symptomatic ventric-






























































































































































































































































AF = atrial fibrillation: CAD - coronary artery disease: DER = defibrillation energy requirement: F - lemule: ICD = implantable cardiovener
defibrillator: M = male: NICM = nonischemic cardiomyopaihy: NSVT = nonsustained ventricular tachycardia: SCD = sudden cardiac death:
VT = ventricular tachycardia: + = present; 0 - absent; — = unavailable.
ular arrhythmias in 8. Nineteen patients had a defibrilla-
tor tuanufactured by Cardiac Pacemakers, Inc. (St. Paul.
MN, USA) and 1 patient each had a defibrillator manu-
factured by Medtronic (Minneapolis, MN, USA) and by
Inlemiedics (Angelton. TX, USA). A transvenous lead
with I (n = 2; Medtronic. Intermedics) or 2 (n — 18;
Cardiac Pacemakers. Inc.) detibrillator coils was used in
20 patients. Epicardial defibrillation and sensing leads
were used in the remaining patient. Toial time fn)m
arrhythmia detection to delivery of shock was 9.5 ± 3.0
seconds. The charging time of the defibrillator after
detection was 5.2 i 2.8 seconds. The generator func-
tioned as a defibrillation electrode in 13 patients. Among
Ihe 20 patients with a transvenous lead. 1 required a
subcutaneous patcb and 1 patient required a single epi-
cardial defibrillation lead.
Defibrillation Energy Requirement Determinations
In tbe study patients, the defibrillation energy require-
ment was determined during ibe implantation procedure,
I to 2 days after implant, 2 months later, and 2 months
after amiodarone therapy was initiated. Tbe most re-
cently determined defibrillation energy requirement be-
fore tbe initiation of amiodarone was defined as the
baseline defibrillation energy requirement. The mean
time between defibrillator implantation and baseline de-
fibrillation energy requirement determination was 409 ±
450 days. The mean time interval between the baseline
defibrillation energy requirement and initiation of amio-
darone therapy was 211 ± 212 days.
At eacb defibrillaiion energy requirement determina-
tion, a slcp-down protocol was used (15. 10, 8, 6. 4, 3. 2,
and I J). After ventricular tibrillation was induced using
60-Hz pacing, tbe impiantable defibrillator sensed,
charged, and delivered the defibrillation shock. If normal
rhythm was restored with the first shock, then the step-
down prottK'ol was continued until Ihe first sbock was
ineffective. Wben tbe first shock failed during implanta-
tion testing, the programmed shock energy for the next
ventricular fibrillation induction was 20 J. If ibe 20-J
sbock failed, then a subcutaneous defibrillation electrode
was added to the system, and the step-down protocol was
repeated. At least 5 minutes elapsed between eacb ven-
tricular fibrillation induction.
Amiodarone Administration
Tbe mean total dose of amiodarone before the amio-
darone defibrillation energy requirement determination
was 26.7 ± 1 l.l g. The mean total dose of amiodarone
consisted of a mean amiodarone loading dose of 680 ±
166 mg/day for 12.6 ± 5.9 days, and a total mean
loading dose of 9.1 ± 5.1 g. This was followed by a
maintenance dose of amiodarone 276 ± 100 mg/day.
Tbe total duration of amiodarone therapy before the
amiodarone defibrillation energy requirement determina-
tion was 73 ± 21 days.
At tbe time of defibrillation energy requirement de-
termination 2 months after the initiation of amiodarone
tberapy, a venous blood sample was obtained and the
serum amiodarone and desethylaniitxlitrone concentra-
tiotis determined using high-performance liquid chroma-
tography.
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Pre-amiodarone Post-amiodarone
Figure 1. Comparison of individual defibrillation energy requirements
(DER) before and after chronic oral amiodarone tlierapy.
Statistical Attalysis
Continuous variables are expressed as mean ± 1 SD
and were compared using a paired or unpaired Mest, as
appropriate. Regression analysis was used to assess a
relaiionsliip between two continuous variables. Stepwise
regression analysis was used to test for independence
between variables. A Chi-square or Fisher's exact test
was used to compare nominal variables. P < 0.05 was
considered statistically significant.
Results
The baseline defibrillation energy requirement was
9.4 ± 4.6 J and the defibriliation energy requirement
after amiodarone therapy was 13.7 ± 5,6 J (P = 0.01;
Fig. 1). The defibrillation energy requirement increased
by 4.0 ± 5.3 J or 62% ± 74%. The shocking resistance
before (47 ± 12 O) and after amiodarone therapy (46 ±
7 li) did not change .significantly (P = 0.8).
The mean amiodarone. desethylamiodarone, and com-
bined amiodarone-desethylainiodarone concentrations
were I.I ± 0.56 mg/dL. 1.0 ± 0.44 mg/dL. and 2.1 ±
0.96 mg/dL, respectively. There was a linear relationship
between the serum amiodarone concentration and the
detibrillation energy requirement (r = 0.6, P = 0.02). tbe
change in defibrillation energy requirement (r ^ 0.8. P =
0.001), and the percent change in deftbrillation energy
requirement (r ^ 0.7, P = 0.004; Fig. 2). The serum
desethylamiodarone concentration also demon.strated a
linear relationship with the defibrillation energy require-
ment (r = 0.6, P = 0.02), change in tbe defibrillation
energy requirement (r = 0.8, P = 0.002), and percent
change in the defibrillation energy requirement (r = 0.7,
P = 0.003; Fig. 3). Additionally, a linear relationship
was observed between the combined amiodarone-deseth-
ylamiodarone concentrations and the defibrillation en-
ergy requirement (r = 0.6, P = 0,01), cbange in the
detibrillation energy requirement (r = 0.7, P = 0.002),
and percent change in defibrillation energy requirement
(r = 0.7, P = 0.002; Fig. 4). Stepwise regression analysis
of amiodarone, desethylamiodarone, and combined
amiodarone-desethvlamiodarone concentrations demon-
strated that only the combined concentrations of amio-
darone and desethylamiodarone were independently as-
sociated with the defibriilation energy requirement.
Tbere was no relationship between the defibriliation
energy requirement and tbe daily amiodarone dose (P =
0.6), duration of amiodarone therapy (P - 0.2), total
dose of amiodarone (P = 0,1), or interval between the
defibrillation energy requirement determinations (P =
0.4). No clinical characteristics, including age, gender,
ejection fraction, type of heart disease, or indication for
implantable defibrillator therapy, correlated with the de-
fibrillation energy requirement, change in defibrillation




The results of this prospective study demonstrate that
chronic amiodarone therapy increases the defibrillation
energy requirement by approximately 60%. Furthermore,
the combined serum concentrations of amiodarone and
desethylamiodarone independently correlate with the de-
fibrillation energy requirement after initiation of amio-
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Figure 2. Correlation of serum amiodarone concentrations with defi-
hrillation energy requirement (DER: top panel) and change in defi-
brillation energy requirement {bottom panel).
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Figure 3. Corretation of .serum desethytamiodarone IDEA) concentra-
tion with dejibriltation energy requirement (DER: top panel) and
ctiange in defibrillation energy requirement (bottom panel).
darone therapy in patients with an implantable defibril-
lator.
Mechanism
The mechanism of amiodarone's effects on the defi-
brillation energy requirement is unclear, perhaps because
the mechanism of successful detibrillation is controver-
sial. Some investigators proposed tbat a defibrillation
shock must be of sufficient energy to depolarize tbe
myocardium in varying states of refractoriness.'' Tbis
results in uniform ventricular refractoriness and termina-
tion of tbe fibrillation. Amiodarone and its metabolite
desetbylamiodarone increase action potential duration by
blocking potassium channels.'"" Amiodarone's Class
III effects may increase the volume of refractory myo-
cardium, tbcrcby necessitating a stronger shock for suc-
ces.sful defibrillation.
Previous Studies
This is the first published .study to compare the defi-
brillation energy requirement before and after tbe initia-
tion of oral amiodarone therapy. The present study eval-
uated tiiis relationship only with biphasic defibrillation.
Tbis is also tbe first published study to demonstrate that
the amiodarone and desetbylamiodarone concentrations
correlate witb tbe biphasic defibrillation energy require-
ment.
Only one previous study evaluated the relation.ship
between amiodarone and desethylamiodarone concentra-
tions and the defibrillation energy requirement.** In tbat
study, amiodarone therapy correlated with an increased
monophasic defibriilation energy requirement and a
bigher frequency of a subcutaneous defibrillation elec-
trode use.^ However, tbe drug concentration did not
correlate with defibrillation efficacy.^ Tbe difference be-
tween tbat previous study and the present study may be
due to different effects of amiodarone on bipbasic and
monophasic defibrillation.
Limitatiotis
Tbe major limitation of this study is the small sample
size. Second, this study did not control for tbe effect of
time on the defibrillation energy requirement. The mean
time lrom defibrillator implantation to tbe study's base-
line detibrillation requirement determination was 4(X)
days. If bipbasic defibrillation efficacy cbanges over
time, it occurs witbin 2 months of implantation and then
probably remains stable over at least 2 years.'^"'''





Figure 4. Corretation of combined serum concentration of amiodarone
and deseihylamiodarone (amiodarotie + DEA) with defibrittatton en-
ergy requirement (DER: lop panel) cini/ ctiange in defibrittanoii energy
requirement itwttom panel).
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Clinical Implications
The results of this study suggest that the defihrillation
energy requirement .should he determined 2 to 3 months
after amiodarone therapy is initiated in patients with an
implantahle defibrillator. This may he especially impor-
tant for patients in whom increases in the defibrillation
energy requirement may compromise the defibrillator
safety margin.
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